期刊文献+

2型糖尿病患者骨密度与胰岛素水平的相关性研究 被引量:17

Correlation between Bone Mineral Density and Insulin Level in Type 2 Diabetic Patients
在线阅读 下载PDF
导出
摘要 目的探讨2型糖尿病患者骨密度的变化及其与空腹血浆胰岛素(FPI)水平的关系。方法应用双光能X线吸收法(DEXA)测定104例2型糖尿病患者(观察组)和46例健康者(对照组)腰椎L1~L4、股骨近端及全身骨密度,用化学发光法测定FPI水平。结果(1)观察组和对照组受检者的FPI水平分别为(1.05±0.40)μU/ml和(0.91±0.25)μU/ml,差异有统计学意义(P<0.05);但两组受检者腰椎、股骨颈及全身骨密度〔分别为(1.12±0.20)g/cm2与(1.09±0.19)g/cm2、(0.89±0.16)g/cm2与(0.90±0.12)g/cm2、(0.95±0.16)g/cm2与(0.92±0.30)g/cm2〕比较,差异均无统计学意义(P>0.05)。(2)观察组和对照组受检者的骨质疏松症患病率分别为14.4%(15/104)和6.5%(3/46),差异无统计学意义(P>0.05)。(3)将2型糖尿病患者分为2型糖尿病骨量正常组(NBMD组)和2型糖尿病骨量低下组(IBMD组),两组患者的平均年龄、FPI水平及使用胰岛素达1年以上者所占比例〔分别为(56.5±12.5)岁与(62.4±9.8)岁、(1.12±0.39)μU/ml与(0.91±0.38)μU/ml、35.8%与8.1%〕比较,差异均有统计学意义(P<0.05)。结论2型糖尿病患者骨密度与健康者相当;高水平的FPI对骨密度有保护作用。 Objective To study the change of bone mineral density (BMD) and its relationship with the level of fasting plasma insulin (EPI) in patients with type 2 diabetes mellitus (T2DM). Methods Dural energy X-ray absorptiometry was used to measure the BMD of the lumbar spines (L1-L4), proximal femur and bones of the whole body in 104 T2DM patients and 46 normal controls, and the chemiluminescent immunoassay (CLIA) was used to determine the EPI level. Results (1) The FPI levels of the trial group and control group were (1.05 ± 0.40) μ U/mL and (0.91 ± 0.25) μ U/mL respectively (P〈0.05), The levels of BMD of the lumbar spines (L1-L4), proximal femur and bones of the whole body were respectively (1.12 ± 0.20) g/cm^2, (0.89 ± 0.16) g/cm^2 and (0.95 ± 0.16) g/cm^2 in the trial group, showed significant differences as compared with (0.92 ± 0.30) g/cm^2, (0.90 ± 0.12) g/cm^2 and ( 1.09 ± 0.19) g/cm^2 respectively in the control group (P〉0.05) . (2)The prevalence rates of osteoporosis in the two groups were respectively 14.4% ( 15/104 ) and 6.5% ( 3/46 ) (P〉0.05) . (3) The diabetic patients were subdivided into NBMD group (T2DM with normal BMD) and IBMD group (T2DM with impaired BMD), then the average age in the NBMD group and IBMD group were (56.5 ± 12.5) and (62.4_± 9.8) respectively, FPI levels were (1.12 ± 0.39) μU/mL (0.91 ±0.38) μU/mL respectively, and the ratio of patients whose times of insulin application being more than one year accounted for 35.8% and 8.1% respectively (P〈0.05) . Conclusion The BMD of type 2 diabetic patients is similar to healthy people, and a higher level of insulin can protect BMD to some extent.
作者 孙雯雯 王立
出处 《中国全科医学》 CAS CSCD 北大核心 2009年第23期2119-2120,2123,共3页 Chinese General Practice
关键词 糖尿病 2型 胰岛素 骨密度 Diabetes mellitus,type 2 Insulin Bone density
  • 相关文献

参考文献7

二级参考文献26

  • 1夏志道,陈璐璐,刘忠厚.骨质疏松症治疗的生物物理学基础[J].中国骨质疏松杂志,1998,4(1):47-50. 被引量:8
  • 2Munoz T M,Calcif Tissue Int,1996年,58卷,5期,316页
  • 3Kwon D J,J Obstet Gynaecol Res,1996年,22卷,2期,157页
  • 4Kao C H,Nucl Med Commun,1993年,14卷,5期,373页
  • 5Kanisis,Melton LJ,Christiansen C,et al The diagnosis of osteoporosls.Bone Miner Res 1994;9(8):1137
  • 6Rocha M, Nava LE, Vazquez de la Torre C, et al. Clinical and radiological improvement of periodontal disease in patients with type 2 diabetes mellitus treated with alendronate: a randomized, placebo-controlled trial. J Periodontol 2001; 72(2):204-9
  • 7Barrett-Connor E, Ensrud KE, Harper K, et al. Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in w
  • 8Nicodemus KK, Folsom AR. Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care 2001; 24(7): 1192-7
  • 9Oleksik AM, Duong T, Pliester N, et al. Effects of the selective estrogen receptor modulator, raloxifene, on the somatotropic axis and insulin-glucose homeostasis. J Clin Endocrinol Metab 2001; 86(6): 2763- 8
  • 10王维力.糖尿病性骨质疏松症[A].见:刘忠厚主编.骨质疏松学[C].北京:科技出版社,1998.576~583.

共引文献98

同被引文献193

引证文献17

二级引证文献92

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部